DelveInsight’s “Graft versus Host Disease (GVHD) - Market Insights, Epidemiology and Market Forecast-2023” report provides an overview of the disease and global historical and forecasted epidemiological data for the diagnosed incident cases of Hematopoietic stem cell transplantations (HSCTs) and Graft Versus Host Disease (GVHD) based upon the sub-types of GVHD along with the type of donor involved in the HSCTs, for the forecast period (2013-2023). The report also includes global market size of the Graft Versus Host Disease (GVHD) for the 7MM (United States, EU5 (France, Germany, Italy, Spain and UK) and Japan.
GVHD is one of the severe complications associated with Hematopoietic stem cell transplantations (HSCTs). DelveInsight forecasts predict an on-going increase in HSCTs in the near future which shall lead to subsequent increase in the patient population of GVHD. According to DelveInsight’s estimates, the total number of diagnosed incident cases of Hematopoietic Stem Cell Transplants (HSCTs) shall increase at a Compound Annual Growth Rate (CAGR) of 2.92%, 2.73% and 2.71% for U.S., EU5 and Japan, respectively, from 2013 to 2023.
The incident rate of GVHD in unrelated donor (URD) is much higher in comparison to the sibling donors (SD), irrespective of the sub-types i.e., acute GVHD (aGVHD) or chronic GVHD (cGVHD). For the United States, as per DelveInsight forecasts, the diagnosed incidence cases of aGVHD in sibling donors and aGVHD in unrelated donors, shall increase at a CAGR of 1.00% and 4.14%, respectively, from 2013-2023. In case of cGVHD, the number of diagnosed incident population cGVHD in sibling donors and cGVHD in unrelated donors is expected to accentuate at a CAGR of 1.00% and 4.14%, respectively, by the end of the year 2023.
The market size of GVHD mainly comprises of the off-label biologics. Many companies are working on the development of targeted therapy and in the near future, these drugs may create an impact on the overall market size of GVHD. DelveInsight’s estimates suggest that the global forecasted market size of Graft Versus Host Disease (GVHD) shall increase at a CAGR of 5.47% from 2013 to 2023.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Scope
- Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
- It focuses on the risk factors and the historical trends of the diagnosed incident cases of allogeneic Hematopoietic Stem Cell Transplants (HSCTs) ( which also includes the cases of first transplants along with the total transplants)
- The Report also covers the detailed historical and forecasted number of diagnosed incident cases of acute GVHD and chronic GVHD, segmented by the type of donors (Sibling donors and unrelated donors) for 7MM from 2013-2023.
- The Report also includes historical and forecasted Market size of GVHD for 7MM from 2013 to 2023.
- It provides the information of available marketed therapies, including off-label biologics, patent and exclusivity details.
- The report also focuses on the details of pipeline drugs in the pivotal stage of development including their SWOT Analysis and expected launch date, which shall help to predict the impact of those drugs on the market size in the near future.
'
Graft Versus Host Disease (GVHD)
Disease Definition
Disease Types
Acute GvHD
Chronic GvHD
Grades of GvHD
Pathophysiology
Risk Factors for GVHD
Diagnosis
Epidemiology and Patient Population
Key Points:
UNITED STATES
Assumptions and Rationale
Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United States
Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States
Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States
EUROPE
Assumptions and Rationale
Germany
Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Germany
Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany
Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany
France
Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in France
Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France
Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France
Spain
Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Spain
Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain
Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain
Italy
Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Italy
Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy
Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy
United Kingdom
Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United Kingdom
Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in UK
Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in UK
JAPAN
Assumptions and Rationale
Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Japan
Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan
Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan
Treatment Algorithm
Guidelines and Recommendations for Treatment of GvHD
Europe
Japan
United States
Current Unmet Needs of Graft Versus Host Disease (GVHD)
Marketed Drugs
Temcell HS
Regulatory Milestones
Advantages & Disadvantages
Product Profile
Safety and Efficacy of Temcell HS
Side effects of Temcell HS
SWOT Analysis of Temcell HS
Remicade
Regulatory Milestones
Advantages & Disadvantages
Product Profile
Safety and Efficacy of Remicade
Side effects of Remicade
SWOT Analysis
Lemtrada
Regulatory Milestones
Advantages & Disadvantages
Product Profile
Safety and Efficacy of Lemtrada
Adverse reactions of Lemtrada
SWOT Analysis
Velcade
Regulatory Milestones
Advantages & Disadvantages
Product Profile
Safety and Efficacy of Velcade
Side effects of Velcade
SWOT Analysis
Gleevec
Regulatory Milestones
Advantages & Disadvantages
Product Profile
Safety and Efficacy of Gleevec
Adverse reactions of Gleevec
SWOT Analysis
Rapamune
Regulatory Milestones
Advantages & Disadvantages
Product Profile
Safety and Efficacy of Rapamune
Adverse reactions of Rapamune
SWOT Analysis
Simulect
Regulatory Milestones
Advantages and Disadvantages
Product Profile
Safety and Efficacy of Simulect
Side effects of Simulect
SWOT Analysis
Enbrel
Regulatory Milestones
Advantages and Disadvantages
Product Profile
Safety and Efficacy of Enbrel
Side effects of Enbrel
SWOT Analysis
Orencia
Regulatory Milestones
Advantages and Disadvantages
Product Profile
Safety and Efficacy of Orencia
Side effects of Orencia
SWOT Analysis
Nulojix
Regulatory Milestones
Advantages and Disadvantages
Product Profile
Safety and Efficacy of Nulojix
Side effects of Orencia
SWOT Analysis
Emerging Drugs Analysis
Emerging Drugs
Begelomab
Regulatory Milestones
Clinical Development
Product Profile
Clinical Pipeline Activity
Ongoing Trials Information
Clinical Trial by Phase
SWOT Analysis
Budesonide
Regulatory Milestones
Clinical Development
Product Profile
Clinical Pipeline Activity
Ongoing Trials Information
Clinical Trial by Phase
SWOT Analysis
Methoxsalen
Regulatory Milestones
Clinical Development
Product Profile
Clinical Pipeline Activity
Ongoing Trials Information
Clinical Trial by Phase
SWOT Analysis
Market Size
Global Market Size of GVHD
Total Market Size of GVHD
Region-Wise Market size of GVHD
UNITED STATES
Total Market Size of GVHD
Market Size of GVHD by Treatment Type
EUROPE
Spain
Total Market Size of GVHD
Market Size of GVHD by Treatment Type
United Kingdom
Total Market Size of GVHD
Market Size of GVHD by Treatment Type
France
Total Market Size of GVHD
Market Size of GVHD by Treatment Type
Italy
Total Market Size of GVHD
Market Size of GVHD by Treatment Type
Germany
Total Market Size of GVHD
Market Size of GVHD by Treatment Type
JAPAN
Total Market Size of GVHD
Market Size of GVHD by Treatment Type
Market Drivers
Market Barriers
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight
Table 1: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United States (2013-2023)
Table 2: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States (2013-2023)
Table 3: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States (2013-2023)
Table 4: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Germany (2013-2023)
Table 5: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany (2013-2023)
Table 6: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany (2013-2023)
Table 7: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in France (2013-2023)
Table 8: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France (2013-2023)
Table 9: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France (2013-2023)
Table 10: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Spain (2013-2023)
Table 11: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain (2013-2023)
Table 12: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain (2013-2023)
Table 13: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Italy (2013-2023)
Table 14: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy (2013-2023)
Table 15: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy (2013-2023)
Table 16: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United Kingdom (2013-2023)
Table 17: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United Kingdom (2013-2023)
Table 18: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United Kingdom (2013-2023)
Table 19: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Japan (2013-2023)
Table 20: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan (2013-2023)
Table 21: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan (2013-2023)
Table 22: GVHD Prophylaxis regimen for Myeloablative conditioning
Table 23: GVHD Prophylaxis regimen for Reduced intensity conditioning
Table 24: Begelomab, Clinical Trials by Zone, 2017
Table 25: Clinical Trials by Recruitment status, 2017
Table 26: Budesonide, Clinical Trials by Zone, 2017
Table 27: Clinical Trials by Recruitment status, 2017
Table 28: Methoxsalen, Clinical Trials by Zone, 2017
Table 29: Clinical Trials by Recruitment status, 2017
Table 30: Total Market size of GVHD in USD, Million (2013-2023)
Table 31: Total Market size of GVHD (Region-Wise) in USD, Million (2013-2023)
Table 32: US market size of GVHD in USD, Million (2013-2023)
Table 33: US market size of GVHD by treatment type in USD, Million (2013-2023)
Table 34: Spain market size of GVHD in USD, Million (2013-2023)
Table 35: Spain market size of GVHD by treatment type in USD, Million (2013-2023)
Table 36: UK market size of GVHD in USD, Million (2013-2023)
Table 37: UK market size of GVHD by treatment type in USD, Million (2013-2023)
Table 38: France market size of GVHD in USD, Million (2013-2023)
Table 39: France market size of GVHD by treatment type in USD, Million (2013-2023)
Table 40: Italy market size of GVHD in USD, Million (2013-2023)
Table 41: Italy market size of GVHD by treatment type in USD, Million (2013-2023)
Table 42: Germany market size of GVHD in USD, Million (2013-2023)
Table 43: Germany market size of GVHD by treatment type in USD, Million (2013-2023)
Table 44: Japan market size of GVHD in USD, Million (2013-2023)
Table 45:Japan market size of GVHD by treatment type in USD, Million (2013-2023)
